Stock·NYSE·Consumer Defensive
Colgate-Palmolive Co. (CL)
- Market cap
- $73.48B
- P/E
- 36.29
- Dividend yield
- 2.29%
- Street target
- $100.00median of 21 analysts
- 52-week range
- $74.55 $99.33
CL stock forecast today
Where CL stands today, and what CleaRank Financial AI makes of it.
CL at a glance
Colgate-Palmolive Co. (CL): Buy, 68/100 on CleaRank's AI score.
- Trend Up: the price is above both its 50- and 200-day moving averages ($89.39 and $89.53).
- Volatility Daily moves average 1.53% (30-day standard deviation).
Figures as of October 27, 2026.
CleaRank Financial AI
CleaRank rates Colgate-Palmolive Co. (CL) Buy, with a model score of 68/100.
The trend lifts the score most: the price is 2.95% above its 200-day average and 3.11% above its 50-day average. The 50-day average stands at $89.39 and the 200-day at $89.53.
Only on CleaRank
Figures we compute ourselves from CL's own price history. Tap one to see it in context.
CL stock price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
3/4Price above its 50-day average ›
The price of $92.17 is 3.1% above the 50-day simple moving average of $89.39.Price above its 200-day average ›
The price is 2.9% above the 200-day simple moving average of $89.53.50-day average above the 200-day ›
The 50-day average ($89.39) is 0.2% below the 200-day average ($89.53), the arrangement of a falling longer-term trend.In the upper half of its 52-week range ›
The price sits at 71% of its 52-week range, between $74.55 and $99.33.
CL share price
Pick a period: each tab shows how far CL has moved over it, to the last close.
Today's trading
Where CL sits inside today's range and its 52-week range.
CL fundamentals and valuation
Valuation against the sector, and the revenue and earnings behind it.
Key statistics
The headline figures for CL.
As of October 27, 2026, CL trades at $92.17, with a market value of $73.48B, a P/E ratio of 36.29 and a dividend yield of 2.29%.
What the numbers say
CleaRank Financial AI's reading of CL's valuation, growth and risks.
CL gained 18.42% over the past year, with its shares moving between $74.55 and $99.33 during that span.
Day to day, the price moves 1.53% on average (the 30-day standard deviation of daily returns).
Colgate-Palmolive Co. (CL) shows a typical daily swing of 1.53% on an average session, and its beta against the S&P 500 is 0.32. Day-to-day movement is the first thing to plan around.
CL against the Consumer Defensive sector
How CL compares with the median Consumer Defensive stock CleaRank tracks.
Price to earnings vs sector: CL trades at a significant premium to sector peers (+50%), suggesting market expectations for superior growth or market position.
Return vs SPY: Since May 15, 2025, CL has gained 2.8% against a gain of 30.4% for SPY.
Performance against SPY
CL and the S&P 500 (SPY) over the same days.
Revenue and earnings
How much CL sells, and how much of it becomes profit.
Revenue growth: Revenue grew 1.4% in FY2025 to $20.4B, from $20.1B a year earlier.
Profit margin: The net margin was 11.1% in FY2025, down from 15.2% the year before.
Profitable: CL earned $2.3B in FY2025.
Earnings reality check
Did CL beat what analysts expected, and how did the stock react?
Earnings record: CL beat the analyst estimate in 7 of the last 7 quarters.
Market reaction: The stock fell in the first session after 5 of those 7 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Jul 31, 2026after close | $0.95 | $0.99 | +4.21% | -1.56% | +2.16% |
| May 1, 2026after close | $0.94 | $0.97 | +3.19% | -2.17% | +0.33% |
| Jan 30, 2026after close | $0.91 | $0.95 | +4.40% | +1.77% | +4.56% |
| Oct 31, 2025after close | $0.89 | $0.91 | +2.25% | -2.69% | +2.22% |
| Aug 1, 2025after close | $0.89 | $0.92 | +3.37% | -0.18% | +1.41% |
| Apr 25, 2025after close | $0.86 | $0.91 | +5.81% | -3.14% | -3.65% |
| Jan 31, 2025after close | $0.89 | $0.91 | +2.25% | +0.38% | +0.07% |
As of October 27, 2026, CL has beaten the analyst EPS estimate in 7 of its last 7 reported quarters and fell in the first trading session after 5 of those beats; its latest report, on July 31, 2026, came in 4.21% above the estimate and the stock moved -1.56% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
CL AI analysis and technical indicators
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
3/3RSI not overbought or oversold ›
The 14-day RSI is 53.9, in neutral territory.RSI above 50 ›
An RSI of 53.9 is above the 50 midpoint, so buyers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is positive, so the 12-day average is above the 26-day average.
CleaRank Financial AI analysis of CL
The score, the reasoning behind it, and what could move the price next.
CL keeps an upward trend, priced at $92.17: 3.11% above its 50-day average of $89.39 and 2.95% above its 200-day average of $89.53. At 71% of its 52-week range, the price is 7.21% below the 52-week high of $99.33. The averages lag the price: the 50-day is 0.15% below the 200-day.
The short and long run point different ways: the price rose 7.10% over the past month, fell 0.60% over the past three months and rose 18.42% over the past year. On momentum, the 14-day RSI reads 53.9, in the neutral zone, with the MACD line positive.
- Two levels deserve attention: the 52-week high of $99.33, which sits above the price, and the 20-day EMA at $91.50, which sits below it.
- The 14-day RSI reads 53.9, in the neutral zone, with the MACD line positive; readings above 70 or below 30 mark stretched momentum.
CL trades above its 50-day and 200-day moving averages ($89.39 and $89.53), which is what makes the trend up; losing the 200-day would be the first warning. The nearest level under the price is the 20-day EMA at $91.50.
CL has the 52-week high of $99.33 as its next level overhead. The 14-day RSI sits at 53.9, which is in the neutral band between 40 and 60.
Technical indicators
Momentum and trend for CL, from its daily closes.
As of October 27, 2026, with CL at $92.17, its 14-day RSI is 53.9 (neutral territory), its 50-day simple moving average is $89.39 and its 200-day is $89.53.
Calculated by CleaRank on daily closes as of October 27, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26). How we calculate these
What CL moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 27, 2026, CL's 1-year correlation of daily returns is -0.01 with S&P 500 (SPY), -0.16 with Nasdaq 100 (QQQ), -0.14 with Bitcoin (BTC) and -0.02 with gold (XAU).
CL price target and analyst forecast
The analysts' target range and how their ratings split.
Analysts checks
2/3Most analysts rate it a buy ›
13 of 21 analysts rate it a buy or strong buy, 7 a hold and 1 a sell.Median target above the price ›
The median 12-month target of $100.00 is 8.5% above the price.More buy ratings than three months ago ›
13 of 21 rate it a buy now, against 13 of 21 three months ago.
CL Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 19, 2026 | JP Morgan | Maintains | Overweight |
| Oct 5, 2026 | Wells Fargo | Maintains | Equal-Weight |
| Sep 21, 2026 | Piper Sandler | Maintains | Overweight |
| Sep 8, 2026 | RBC Capital | Reiterates | Outperform |
| Aug 3, 2026 | UBS | Maintains | Buy |
| Aug 3, 2026 | TD Cowen | Maintains | Hold |
As of October 27, 2026, 21 Wall Street analysts cover CL: 13 rate it a buy or strong buy, 7 a hold and 1 a sell or strong sell. Their 12-month price targets range from $87.00 to $110.00. The median CL price target is $100.00, 8.5% above the price of $92.17.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
CL trade plan: entry, stop loss and targets
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
CL trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Long entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from CL's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much CL tends to move, against the market and on its own.
CL price history and drawdowns
CL's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
1/2Average daily move under 2% ›
The price has moved 1.53% on an average day (30-day standard deviation of daily returns).Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $16,689, against $42,015 in the S&P 500 (SPY).
CL Drawdowns & Recovery
As of October 27, 2026, CL's worst peak-to-trough fall over the last 10 years with dividends reinvested was -27.8% (September 2024 to December 2025); it is still 10.5% below that peak, and 62% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into CL in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: CL trailed the S&P 500 over this period: $16,689 against $42,015.
A $10,000 investment in CL in October 2016 would be worth about $16,689 today with dividends reinvested, compared with about $42,015 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to CL, and which have not.
Strongest month, November: an average of +2.81%, up in 8 of 10 years.
Weakest month, September: an average of -2.64%, up in 2 of 10 years.
This month, October: has averaged -2.14%, up in 4 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, CL's strongest calendar month has been November (average +2.81%, up in 8 of 10 years) and its weakest September (average -2.64%, up in 2 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
CL stock price prediction 2030
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in CL, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 4-year Monte Carlo simulation, based on 10 years of price history, projects that a $10,000 investment in CL today could grow to about $11,988 by 2030 in the base case, with a 90th-percentile outcome near $20,054 and a 10th-percentile outcome around $7,166. The simulation models price only; at today's 2.29% yield, dividends would add to these figures. Projections are statistical simulations, not guarantees.
CL Stock Price Prediction 2030: Simulated Scenarios
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $110 for CL by 2030 in the base case, from $92.17 today (1.2x over 4 years). The 10th-percentile path ends near $66.05. These are outcomes of a Monte Carlo simulation run on CL's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $74.57 | $96.44 | $125 | |
| 2028 | $70.14 | $101 | $145 | |
| 2029 | $67.63 | $106 | $165 | |
| 2030 | $66.05 | $110 | $185 |
Method: a lognormal simulation of CL's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles. How the simulation works
CL insider trading
What the people running the company have bought and sold.
CL insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Net insider selling: No insider bought CL shares on the open market in the last 18 months. Sales are often planned in advance or cover tax on vesting shares, so they say less than purchases would.
As of October 27, 2026, CL insiders reported 14 open-market sales worth $57.3M and no open-market purchases over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Aug 24, 2026 | Panagiotis Tsourapas
Officer
|
Sell | 10.0K | $920.5K |
| Aug 6, 2026 | John T Cahill
Director
|
Sell | 4.2K | $389.4K |
| Aug 6, 2026 | John T Cahill
Director
|
Option | 4.2K | $298.4K |
| Aug 5, 2026 | Noel R Wallace
Chief Executive Officer
|
Sell | 322.0K | $29.7M |
| Aug 5, 2026 | Noel R Wallace
Chief Executive Officer
|
Option | 322.0K | $23.3M |
| Jul 1, 2026 | John P. Bilbrey
Director
|
Grant | 265 | $23.7K |
| Jul 1, 2026 | Brian Newman
Director
|
Grant | 209 | $18.7K |
| Jul 1, 2026 | Lorrie M Norrington
Director
|
Grant | 293 | $26.2K |
| May 15, 2026 | Gregory Malcolm
Officer
|
Sell | 2.3K | $203.4K |
| May 11, 2026 | John P. Bilbrey
Director
|
Grant | 2.1K | - |
| May 11, 2026 | Christopher S Boerner
Director
|
Grant | 1.4K | - |
| May 11, 2026 | John T Cahill
Director
|
Grant | 2.1K | - |
| May 11, 2026 | Lisa Marie Edwards
Director
|
Grant | 2.1K | - |
| May 11, 2026 | C. Martin Harris, M.D.
Director
|
Grant | 1.6K | - |
| May 11, 2026 | Martina Hund-Mejean
Director
|
Grant | 2.1K | - |
| May 11, 2026 | Kimberly A. Nelson
Director
|
Grant | 2.1K | - |
| May 11, 2026 | Brian Newman
Director
|
Grant | 2.1K | - |
| May 11, 2026 | Lorrie M Norrington
Director
|
Grant | 2.1K | - |
| May 7, 2026 | Sally Massey
Officer
|
Sell | 8.6K | $751.6K |
| Apr 1, 2026 | John P. Bilbrey
Director
|
Grant | 266 | $23.7K |
| Apr 1, 2026 | Brian Newman
Director
|
Grant | 210 | $18.7K |
| Apr 1, 2026 | Lorrie M Norrington
Director
|
Grant | 294 | $26.2K |
| Feb 23, 2026 | Jennifer M. Daniels
Officer
|
Grant | 25.7K | - |
| Feb 23, 2026 | John Hazlin
Officer
|
Grant | 12.8K | - |
| Feb 23, 2026 | Gregory Malcolm
Officer
|
Grant | 6.3K | - |
| Feb 23, 2026 | Sally Massey
Officer
|
Grant | 16.8K | - |
| Feb 23, 2026 | Stanley J Sutula III
Chief Financial Officer
|
Grant | 38.7K | - |
| Feb 23, 2026 | Panagiotis Tsourapas
Officer
|
Grant | 25.7K | - |
| Feb 23, 2026 | Noel R Wallace
Chief Executive Officer
|
Grant | 136.7K | - |
| Feb 12, 2026 | Panagiotis Tsourapas
Officer
|
Sell | 50.0K | $4.8M |
| Feb 12, 2026 | Panagiotis Tsourapas
Officer
|
Option | 50.0K | $3.8M |
| Feb 10, 2026 | John Hazlin
Officer
|
Sell | 21.0K | $2.0M |
| Feb 10, 2026 | John Hazlin
Officer
|
Option | 21.0K | $1.6M |
| Feb 6, 2026 | Gregory Malcolm
Officer
|
Sell | 12.7K | $1.2M |
| Feb 6, 2026 | Gregory Malcolm
Officer
|
Option | 12.7K | $974.0K |
| Feb 5, 2026 | Sally Massey
Officer
|
Sell | 15.9K | $1.5M |
| Feb 5, 2026 | Sally Massey
Officer
|
Option | 15.9K | $1.2M |
| Feb 4, 2026 | Stanley J Sutula III
Chief Financial Officer
|
Sell | 97.8K | $9.2M |
| Feb 4, 2026 | Noel R Wallace
Chief Executive Officer
|
Sell | 45.6K | $4.3M |
| Feb 4, 2026 | Jennifer M. Daniels
Officer
|
Sell | 22.0K | $2.1M |
| Feb 4, 2026 | Jennifer M. Daniels
Officer
|
Option | 22.0K | $1.6M |
| Feb 4, 2026 | Stanley J Sutula III
Chief Financial Officer
|
Option | 97.8K | $8.0M |
| Jan 2, 2026 | John P. Bilbrey
Director
|
Grant | 301 | $23.7K |
| Jan 2, 2026 | Brian Newman
Director
|
Grant | 238 | $18.7K |
| Jan 2, 2026 | Lorrie M Norrington
Director
|
Grant | 333 | $26.2K |
| Nov 21, 2025 | Sally Massey
Officer
|
Sell | 1.2K | $100.1K |
| Oct 1, 2025 | John P. Bilbrey
Director
|
Grant | 289 | $23.7K |
| Oct 1, 2025 | Brian Newman
Director
|
Grant | 228 | $18.7K |
| Oct 1, 2025 | Lorrie M Norrington
Director
|
Grant | 319 | $26.2K |
| Sep 11, 2025 | Jennifer M. Daniels
Officer
|
Grant | 4.6K | - |
| Sep 11, 2025 | Shane Grant
Officer
|
Grant | 3.6K | - |
| Sep 11, 2025 | John Hazlin
Officer
|
Grant | 4.0K | - |
| Sep 11, 2025 | Gregory Malcolm
Officer
|
Grant | 1.1K | - |
| Sep 11, 2025 | Sally Massey
Officer
|
Grant | 3.5K | - |
| Sep 11, 2025 | Prabha Parameswaran
Officer
|
Grant | 4.6K | - |
| Sep 11, 2025 | Stanley J Sutula III
Chief Financial Officer
|
Grant | 8.3K | - |
| Sep 11, 2025 | Panagiotis Tsourapas
Officer
|
Grant | 4.8K | - |
| Sep 11, 2025 | Noel R Wallace
Chief Executive Officer
|
Grant | 28.3K | - |
| Jul 1, 2025 | John P. Bilbrey
Director
|
Grant | 264 | $23.7K |
| Jul 1, 2025 | Brian Newman
Director
|
Grant | 208 | $18.7K |
| Jul 1, 2025 | Lorrie M Norrington
Director
|
Grant | 292 | $26.3K |
| Jun 16, 2025 | Shane Grant
Officer
|
Grant | 90.0K | - |
| May 15, 2025 | Sally Massey
Officer
|
Sell | 2.3K | $200.2K |
| May 12, 2025 | John P. Bilbrey
Director
|
Grant | 2.0K | - |
| May 12, 2025 | Steven A Cahillane
Director
|
Grant | 2.0K | - |
| May 12, 2025 | John T Cahill
Director
|
Grant | 2.0K | - |
| May 12, 2025 | Lisa Marie Edwards
Director
|
Grant | 2.0K | - |
| May 12, 2025 | C. Martin Harris, M.D.
Director
|
Grant | 1.5K | - |
| May 12, 2025 | Martina Hund-Mejean
Director
|
Grant | 2.0K | - |
| May 12, 2025 | Kimberly A. Nelson
Director
|
Grant | 2.0K | - |
| May 12, 2025 | Brian Newman
Director
|
Grant | 2.0K | - |
| May 12, 2025 | Lorrie M Norrington
Director
|
Grant | 2.0K | - |
Source: TwelveData, from SEC Form 4 filings
CL stock forecast: questions people ask
Answered from the figures on this page, as of October 27, 2026.